Get started
EXELIXIS INCEXELIXIS INCEXELIXIS INC

EXELIXIS INC

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast

1EXEL trade ideas

Trade Idea: Exelixis, Inc. (NASDAQ: EXEL)EXEL is offering a compelling setup, trading just above its 50-day moving average — a key technical level that has historically provided strong support. The stock belongs to a high-quality company with solid financials, reinforcing confidence in the broader trend. With the price stabilizing above this important moving average, a small initial long position looks attractive to participate in potential upside continuation. Entry Strategy: Enter a small long position just above the 50-day moving average to align with the resumption of bullish momentum. Risk Management: Set a protective stop-loss at $35.30, providing a well-defined risk level should the trade move against us. Important Note: Be mindful that earnings are scheduled for May 13th, which could introduce heightened volatility. Consider adjusting position sizing accordingly or tightening risk management ahead of the announcement. DISCLAIMER : The content and materials featured are for your information and education only and are not attended to address your particular personal requirements. The information does not constitute financial advice or recommendation and should not be considered as such. Risk Management is Your Shield! Always prioritise risk management. It’s your best defence against losses.
NASDAQ:EXELLong
by Gihanhemachandra
EXEL Chart Heating Up: Breakout Watch!🔍 Overview: On the 30-minute chart of EXEL (Exelixis, Inc.), we're witnessing a symmetrical triangle breakout forming near a key confluence of support/resistance. This setup could lead to a potential bullish move if confirmed. 📌 Key Technical Highlights: Pattern: Symmetrical triangle Breakout Point: Near $34.85 (marked by yellow circle) Resistance Levels: Minor: $36.07 (red) Major: $37.21 (green) Support Zone: $34.10 (white line) Volume: Moderate, needs confirmation with breakout candle 📈 Trade Plan (Long Bias) ✅ Entry Zone: $34.80 – $35.00 (post breakout confirmation) ❌ Stop Loss (SL): Below $34.10 (trendline & horizontal support) 🎯 Profit Targets: TP1: $36.07 (previous resistance) TP2: $37.21 (major resistance zone from March highs) ⚙️ Risk-Reward Considerations: Symmetrical triangle suggests price compression and upcoming breakout Risk:Reward ratio looks favorable if trade follows upward momentum Confirmation needed with volume breakout + strong candle close above triangle 📚 Educational Takeaway: This is a textbook case of price consolidation followed by breakout anticipation. Symmetrical triangles often act as continuation patterns, and when paired with horizontal support and volume analysis, they offer high-probability trade setups. Traders should always wait for confirmation—breakouts without volume can lead to fakeouts. Set tight stops and manage your trade dynamically as price action unfolds. ✍️ Final Thoughts: If you're actively trading stocks like EXEL, using clean patterns like this combined with defined entry/exit rules can dramatically improve consistency. Keep watching volume and price action for the final signal.
NASDAQ:EXELLong
by ProfittoPath
Setup: EXELEXEL : I have a swing trade setup signal. I'm looking to enter long if the stock can manage to CLOSE above the last candle high(BUY). If triggered, I will then place a stop-loss below (SL) and a price target above it(TP= Sell all or 50%, move SL to breakeven), then using the close below the 10SMA as my trailing stop loss. I like that the last hour candle had high volume showing interest (normally coming from 'Smart Money'). **Note: The above setups will remain valid until the stock CLOSES BELOW my set stop-loss level(SL).
NASDAQ:EXEL
by StockHunter88
Putting the odds in your favor - $EXEL in a green zone pullbackI've said before that trading with the trend is always something that improves your odds, both long and short. I don't ALWAYS trade with the trend but I like to, especially when there's other compelling reasons to. Putting the odds in your favor is always a smart move when trading. On this chart I'm using 2 things to illustrate trend. The GC overlay is simply a pair of moving average ribbons that I use to show me the strength of the trend. Yellow above purple is an uptrend. I usually use green and red which are the default colors, but changed the colors for this in case anyone is red/green colorblind. Almost as important for me, is the gap between the two ribbons. This shows the strength of that trend. You can see that since August, NASDAQ:EXEL has been in a strong uptrend. We like that being the case whenever possible. Now my algo says oversold (and its input is not disputed by me) but it also incorporates some of this. However, the visual here shows that the oversold signal is just as the price is touching the upper part of the yellow ribbon. IF price had collapsed in a hurry into the bottom part of that ribbon or especially through it, I'd be thinking it was more of a trend reversal signal. This is shown by the circle on the chart back in January and again in early-mid April) rather than a temporary pullback. When the price crashes through that band, it's a warning. Listen to it, especially if you trade trends more than the 'noise' that I trade. I also like to have these pullbacks occur in the upper half of the regression channel (the green zone). Again, if my algo says "buy" when it's in the red zone, I still listen. But if my algo says buy on two stocks, but one is in the green, and the other is in the red, I'll take the green almost every time. As always, there are exceptions to the rules, where crashing doesn't signal a trend change or when gradual moves through the band are the beginning of trend changes. But it works often enough to be aware of it. If you open the chart for EXEL and apply this indicator, you'll see lots of other examples where this was a portent of things to come regarding a trend reversal. This works the same way moving up when the yellow ribbon is below the purple one during a bearish period. If there's an upward rip then, the odds just increased for a positive reversal. I am nothing if not a slave to probability when trading. I don't guess or rely on hunches or what some random "pumper" says, trying to get everyone to be on their side of a trade. I make every trading decision based on probability. You should too. It doesn't mean you''ll always be right, but it will increase how often you are. When you're designing a trading system, know the probability behind the decision you're making. If you don't, you're just guessing and most people lose money trading because of that. If you're trading a head and shoulders pattern, for example, do you know the win probability behind it? I doubt it. But you should. You're just trusting that because someone else said it works, that it will this time, on this stock, in this never before seen combined environment of variables. Until you test something on THIS stock, under as many possible conditions as you can, don't be surprised when it fails. I try to post backtest results (or at least partial ones) when I post trades, so you can see WHY I trust the decision I'm making. That testing, and the probability that it indicates, should influence not only the direction of your trade, but stop placements if you use them and even capital allocation. Stronger probabilities warrant stronger conviction and vice versa. I'm not saying if your system says 99% chance of a win, to go all in and then lose it all. Probability and PROBABLY have the same linguistic root for a reason. Probability is NEVER a guarantee. It is a compass for a trade, not military grade GPS. So in the end, all price action, indicators, and patterns are simply elements that can increase the probability of your trades working out. But knowing how they work, and how reliable they are should be a HUGE part of your prep work for trading, long before you ever risk real money on that trade. If not, I hope that money doesn't matter very much to you - because you're likely to lose it. I took this trade at the close today. I'm simply looking to turn a profit, so my goal is any gain above my entry price and then get that capital back to work on another idea. I'm adding as long as my algo says it's oversold and selling each lot as it becomes profitable. EXEL long at 26.06 - wish me luck! I hope you all realize this post was instructional and not an encouragement to take this trade, so if you decide to trade it, good luck, but do your own research first.
NASDAQ:EXELEducation
by redwingcoach
EXEL - 5.96% Potential Profit - Ascending TriangleI'm cautious with this trade. I don't usually get into positions with a risk/reward smaller than 3. - Target Entry: $25.65 - Target Stop Loss: $25.05 - Target Exit: $27.19 - Risk / Reward Ratio: 2.57 About me - Note that I tend to adjust stop losses in order to secure profits early and preserve capital. This means that the target price is going to be achieved as long as there are no strong pullbacks that trigger my new adjusted stop loss
NASDAQ:EXELLong
by maschera
Exelixis is a great opportunityHi guys, hope you are all well. Today we are looking at Exelixis, an oncology-focused biotechnology company that focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The market cap of the firm is roughly $7 billion. What drew me to looking into this company was its cash and cash equivalents value, a whopping $1.2 billion, giving it an almost 20% cash to market cap valuation. The company is forecasted to grow by 40% this year and has absolutely no debt. The P/E is high at a level of 63 however I am not concerned at all by this figure due to the fact that EPS is forecasted to grow by ten fold in the next 3-5 years. From my wave analysis, we can see that the stock consolidated nicely to form its wave 2 and is now in the approach of starting its Wave 3. This is in 1 week time scales, so I do not expect this to be a short term trade. Nevertheless, this really is a fantastic opportunity to possibly triple your investment in the next 2-3 years and I am already positioned in the stock. This is not investment advice, so please do your own due diligence before making any decisions. I hope this is helpful
NASDAQ:EXELLong
by ASA2001
$EXEL - Upwards Momentum and potential breakout1st published idea for my new process which begins with the stock screener. I am trying to identify stocks that have bottomed out or at least hit a lower resistance that begin to have upwards momentum in the RSI coupled with an EMA crossover event. Initial Filters: >2B Market Cap to filter small companies Debt to Equity Ratio (MRQ) < 0.5 to mitigate some risk Average Volume (30 day) > 500k -> We need volume for a big breakout Exchange limited to NYSE and NASDAQ RSI (56 hrs) > 45 -> In order to have a breakout there needs to be upwards momentum in the RSI RSI (28 hrs) between 54 and 70 -> shorter term RSI than the other to show upwards momentum. At any given time this returns around 75 tickers. Next setup alerts on EMA(40hrs) over EMA(120hrs) and EMA(80hrs) over EMA(200hrs). This will result in only a few alerts per day. As they come out check to see if they fit your standard trend analysis for a potential breakout. $EXEL fits the bill perfectly. I am active with a target around $26-$27 short term.
NASDAQ:EXELLong
by maatspencer
Long ideaExelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company’s products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, Exelixis, Inc. is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, and other kinases implicated in growth and spread of cancer. It has collaboration and license agreement with Ipsen Pharma SAS, Takeda Pharmaceutical Company Ltd., Roche, Aurigene Discovery Technologies Limited, Iconic Therapeutics, Inc., Invenra, Inc., StemSynergy Therapeutics, Inc., Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Merck, Daiichi Sankyo Company, Limited, and clinical collaboration with Ipsen. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in Alameda, California. Market Cap $ 5.7B Dividend Yield Beta vs SPX 0.9 Short Interest 4.6% Volatility (1Y) 45.4 Hedge Fund Held Industry Biotechnology Competitors ABBV AMGN GILD VRTX Performance 14.46 Low 18.39 1-Year Price Range 27.42 High 1M 3M YTD 1Y EXEL -15.8% -17.3% 4.4% 13.0% EXEL vs SPX -19.5% -23.1% -8.3% -4.2% Valuation Forward P/E (NTM) 109.9X Trailing P/E (LTM) 38.4X Price/Book 3.1X EV/Sales (LTM) 4.8X EV/EBITDA (LTM) 25.4X Capital Structure Market Cap $ 5.7B Total Debt $ 48.3M Cash $ 1.2B Other Enterprise Value $ 4.6B Earnings Estimates Fiscal Year EPS YoY Sales YoY 2020 0.46 -54.6% $ 930.7M -3.8% 2021 0.82 77.4% $ 1.2B 24.5% 2022 1.48 80.5% $ 1.5B 33.4%
NASDAQ:EXELLong
by pivotanalytics